Time-Activity data fitting in molecular Radiotherapy: Methodology and pitfalls

Phys Med. 2024 Jan:117:103192. doi: 10.1016/j.ejmp.2023.103192. Epub 2023 Dec 5.

Abstract

Absorbed radiation doses are essential in assessing the effects, e.g. safety and efficacy, of radiopharmaceutical therapy (RPT). Patient-specific absorbed dose calculations in the target or the organ at risk require multiple inputs. These include the number of disintegrations in the organ, i.e. the time-integrated activities (TIAs) of the organs, as well as other parameters describing the process of radiation energy deposition in the target tissue (i.e. mean energy per disintegration, radiation dose constants, etc). TIAs are then estimated by incorporating the area under the radiopharmaceutical's time-activity curve (TAC), which can be obtained by quantitative measurements of the biokinetics in the patient (typically based on imaging data such as planar scintigraphy, SPECT/CT, PET/CT, or blood and urine samples). The process of TAC determination/calculation for RPT generally depends on the user, e.g., the chosen number and schedule of measured time points, the selection of the fit function, the error model for the data and the fit algorithm. These decisions can strongly affect the final TIA values and thus the accuracy of calculated absorbed doses. Despite the high clinical importance of the TIA values, there is currently no consensus on processing time-activity data or even a clear understanding of the influence of uncertainties and variations in personalised RPT dosimetry related to user-dependent TAC calculation. As a first step towards minimising site-dependent variability in RPT dosimetry, this work provides an overview of quality assurance and uncertainty management considerations of the TIA estimation.

Keywords: Dosimetry; Radiopharmaceutical therapy; TAC; TIA; Time-activity curve; Time-integrated activities.

MeSH terms

  • Humans
  • Positron Emission Tomography Computed Tomography*
  • Radiometry / methods
  • Radionuclide Imaging
  • Radiopharmaceuticals* / therapeutic use
  • Single Photon Emission Computed Tomography Computed Tomography

Substances

  • Radiopharmaceuticals